Sylvia Merel Brakenhoff

Ms. Sylvia Merel Brakenhoff

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Journal of Hepatology
Verified
Journal Article
Open access
EDEdo J. Dongelmans
Edo J. Dongelmans
GHGrishma Hirode
Grishma Hirode
BHBettina E. Hansen
Bettina E. Hansen
CCChien-Hung Chen
Chien-Hung Chen
TSTung-Hung Su
Tung-Hung Su
HJHarry L.A. Janssen
Harry L.A. Janssen
Flares after nucleos(t)ide analogue (NA) cessation are common and potentially harmful. Predictors of flares are required for risk stratification and to guide off-treatment follow-up. This multicenter cohort study included virally suppressed patients with chronic hepatitis B (CHB) who were hepatitis B e antigen negative at NA cessation. Hepatic flares were defined based on ALT levels of ≥5x, 10x or 20x the upper limit of normal (ULN). Multivariable Cox regression analyses were performed with censoring at retreatment, HBsAg loss or loss to follow-up. A sub-analysis was performed including HBV DNA levels within the first 12 weeks as a time-dependent covariate. Of the 1,552 included patients, 350 developed a flare (ALT ≥5x ULN), of whom 70.6% did within the first year. One-year cumulative incidences for ALT flares ≥5x, ≥10x, ≥20x ULN were 18.6%, 10.2% and 3.4%, respectively. Severity of flares decreased over time, but severe flares still occurred after 1 year. Thirteen patients decompensated after a flare, of whom three died. Flares did not seem to be associated with increased rates of HBsAg loss (adjusted hazard ratio [aHR] 1.42, p = 0.28). Multivariable analyses showed that older age (aHR 1.02, p = 0.001), male sex (aHR 1.57, p = 0.003), HBsAg levels at NA withdrawal (100-1,000 IU/ml; aHR 1.99, p 1,000 IU/ml; aHR 2.65, p <0.001) and tenofovir disoproxil fumarate vs. entecavir therapy (aHR 2.99, p 5log10 IU/ml were associated with the highest risk of flares (aHR 2.36, p <0.001). Flares are common after NA withdrawal, especially within the first year and can result in hepatic decompensation and death. Older age, male sex, higher HBsAg levels at end of treatment and tenofovir therapy were associated with a higher risk of flares. Close monitoring and retreatment should be considered if HBV DNA levels exceed 5log10 IU/ml within the first 12 weeks. This is the first large global multi-centered cohort study which provides detailed data about flares after nucleos(t)ide analogue cessation in patients with chronic hepatitis B. Older age, male sex, higher HBsAg levels at end of treatment and tenofovir therapy were associated with a higher risk of flares. These results could guide follow-up after withdrawal, helping clinicians identify high-risk patients and decide when to restart anti-viral therapy, which we recommend if HBV DNA levels exceed 5log10 IU/ml within the first 12 weeks. not applicable.

21 November 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
RMRobert A. de Man
Robert A. de Man
ABAndré Boonstra
André Boonstra
MCMargo J. H. van Campenhout
Margo J. H. van Campenhout
RKRobert J. de Knegt
Robert J. de Knegt
MSMilan J Sonneveld
Milan J Sonneveld
Summary: Background: Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti‐viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off‐treatment response is yet unclear.Aim: To study the degree of on‐treatment viral antigen decline among patients with pronounced HBV RNA decrease in relation to off‐treatment sustained response and HBsAg loss.Methods: HBV RNA, HBsAg and hepatitis B core‐related antigen (HBcrAg) were quantified in patients with chronic hepatitis B who participated in two randomised controlled trials of peginterferon‐based therapy. Sustained response (HBV DNA 2 log HBV RNA decline or >1 log decline resulting in an undetectable value at on‐treatment week 24), stratified by concomitant HBsAg decline (1 log).Results: We enrolled 279 patients; 176 were hepatitis B e antigen (HBeAg)‐positive, and 103 were HBeAg‐negative. Sustained response was achieved in 20.4% of patients. At on‐treatment week 24, HBV RNA response was associated with higher sustained response rates (27.4% vs 13.0% in non‐responders, P = 0.004). However, among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 log HBsAg decline. Among HBV RNA responders, sustained response was achieved in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log decline (n = 12/75, P = 0.001). Similar results were obtained with HBcrAg and when response was defined as HBsAg loss.Conclusions: In this cohort, many patients with HBV RNA response during peginterferon‐based treatment did not experience HBsAg and/or HBcrAg decline. The absence of concomitant decline in these viral antigens was associated with low rates of treatment response and HBsAg loss. Future trials should therefore consider kinetics of combined biomarkers to assess anti‐viral efficacy.Trial registration, ClinicalTrials.gov: NCT00114361, NCT00146705.

12 September 2021 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
HCHannah S. J. Choi
Hannah S. J. Choi
MSMilan J Sonneveld
Milan J Sonneveld
MFMina S. Farag
Mina S. Farag
WBWillem P. Brouwer
Willem P. Brouwer
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
HJHarry L.A. Janssen
Harry L.A. Janssen

2 July 2022 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
RKRobert J. de Knegt
Robert J. de Knegt
MCMargo J.H. van Campenhout
Margo J.H. van Campenhout
AEAnnemiek A. van der Eijk
Annemiek A. van der Eijk
WBWillem P. Brouwer
Willem P. Brouwer
MSMilan J. Sonneveld
Milan J. Sonneveld
Since ALT flares after therapy withdrawal are associated with adverse outcomes, risk stratification is of major importance. We aimed to study whether off-treatment flares are related with virological outcomes, and if serum levels of novel biomarkers at end-of-treatment (EOT) can predict flares. Chronic hepatitis B patients who participated in three global randomised trials of peginterferon-based therapy were studied (99-01, PARC, ARES). HBV RNA, HBsAg and HBcrAg were quantified at EOT. Associations between EOT biomarker levels and flares were assessed as continuous data and after categorisation. Flares were defined as ALT ≥5xULN during six months after therapy cessation. We included 344 patients; 230 HBeAg-positive and 114 HBeAg-negative. Patients were predominantly Caucasian (77.0%) and had genotype A/B/C/D in 23.3/7.3/13.4/52.3%. Flares were observed in 122 patients (35.5%). Flares were associated with lower rates of sustained response (3.5% vs 26.8% among patients with and without a flare; p < 0.001). Higher HBsAg (OR 1.586, 95%CI 1.231-2.043), HBV RNA (OR 1.695, 95%CI 1.371-2.094) and HBcrAg (OR 1.518, 95%CI 1.324-1.740) levels were associated with higher risk of flares (p < 0.001). Combinations of biomarkers further improved risk stratification, especially HBsAg + HBV RNA. Findings were consistent in multivariate analysis adjusted for potential predictors including HBeAg-status and EOT-response (HBV DNA <200 IU/mL). Off-treatment ALT flares were not associated with favourable virological outcomes. Higher EOT serum HBsAg, HBcrAg and HBV RNA were associated with a higher risk of flares after therapy withdrawal. These findings can be used to guide decision-making regarding therapy discontinuation and off-treatment follow-up. ClinicalTrials.gov: NCT00114361, NCT00146705, NCT00877760.

14 November 2022 in European Journal of Internal Medicine
Verified
Journal Article
Open access
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
WKW.K. Katwaroe
W.K. Katwaroe
LKL.A. van Kleef
L.A. van Kleef
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
RMR.A. de Man
R.A. de Man
MSM.J. Sonneveld
M.J. Sonneveld
The incidence of chronic hepatitis B (CHB) is declining due to successful implementation of vaccination programs and widespread use of antiviral therapy. We aimed to study time-trends in disease characteristics and comorbidities in newly referred CHB patients. We collected information on hepatitis B virus (HBV) related disease characteristics (including hepatitis B e-antigen (HBeAg) status, viremia, stage of liver fibrosis and indication for treatment and/or hepatocellular carcinoma (HCC) surveillance) and presence of comorbidities in all CHB patients referred to our center from 1980 through 2020. Patient characteristics were compared according to referral date (before 2000, between 2000 and 2010 and after 2010). We identified 1515 eligible patients. Patients referred after 2010 were older (36 versus 34 years, p < 0.001), more often non-Caucasian (82.3% versus 55.0%, p < 0.001) and more frequently HBeAg negative (81.5% versus 49.8%, p < 0.001) when compared to patients referred before 2000. Adjusted for ethnicity, sex and age, patients referred after 2010 were less likely to have significant fibrosis (adjusted odds ratio [aOR]:0.178, p < 0.001) or indication for antiviral therapy (aOR:0.342, p < 0.001) but were more likely to be affected by the metabolic syndrome (aOR:1.985, p = 0.013), hepatic steatosis (aOR:1.727, p < 0.001) and metabolic dysfunction associated fatty liver disease (MAFLD) (aOR:1.438, p = 0.013). The characteristics of the CHB populations are changing. Newly referred patients are older, have less active HBV related liver disease but are more likely to be co-affected by MAFLD. These findings provide guidance for adequate allocation of resources to cope with the changing characteristics of the CHB population. Foundation for Liver and Gastrointestinal Research Rotterdam, the Netherlands and Gilead Sciences.

23 May 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
RKRobert J de Knegt
Robert J de Knegt
JOJeffrey Oliveira
Jeffrey Oliveira
AEAnnemiek A van der Eijk
Annemiek A van der Eijk
AVAnneke J van Vuuren
Anneke J van Vuuren
MSMilan J Sonneveld
Milan J Sonneveld
Emerging evidence suggests a pivotal role for B-cell responses in the natural history of chronic hepatitis B. Serum levels of antibodies to hepatitis B core antigen (anti-HBc) vary across infection stages, but their role in predicting response to antiviral therapy is uncertain. Anti-HBc levels were assessed before peginterferon (PEG-IFN) therapy in patients with chronic hepatitis B who either started de novo PEG-IFN (n = 299; 195 hepatitis B e antigen [HBeAg] positive) or started PEG-IFN as add-on to an existing nucleo(s)tide analogue backbone (n = 91; all HBeAg-positive). Associations were explored between anti-HBc and (1) serum biomarkers, (2) liver histological findings, and (3) treatment response. We studied 390 patients. The hepatitis B virus (HBV) genotype were A, B, C, and D in 24%, 9%, 16%, and 49%, respectively; 72% of patients were Caucasian. Among currently untreated HBeAg-positive patients, anti-HBc was correlated with HBV DNA, hepatitis B core-related antigen (HBcrAg), hepatitis B surface antigen (HBsAg), and HBV RNA, but not with alanine aminotransferase (ALT). Higher anti-HBc was associated with more severe histological inflammatory activity (P < .001), irrespective of HBeAg status. After de novo PEG-IFN, higher anti-HBc levels were associated with HBeAg loss, sustained response, HBsAg decline, and HBsAg clearance (P < .050). Among patients treated with add-on PEG-IFN, higher anti-HBc was associated with HBeAg loss (P = .01). Serum anti-HBc levels correlate with histological inflammatory activity. Higher anti-HBc levels were associated with favorable treatment outcomes. These findings suggest that anti-HBc could be used to select patients most likely to respond to immunomodulatory therapy. NCT00114361, NCT00146705, NCT00877760, and NCT01532843.